|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- ||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion: CHRONOS: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 3, 2016
P3, N=739, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed
- triamcinolone acetonide topical / Generic mfg.
Biomarker, Trial primary completion date, IO biomarker, Biopsy: GNE-AD: A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (clinicaltrials.gov) - Oct 27, 2016
P4, N=15, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jan 2017
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=84, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2016 --> Jan 2017 Trial primary completion date: Aug 2016 --> Jan 2016
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2016 --> Jan 2016 Trial primary completion date: Dec 2016 --> Feb 2020
- Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=84, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2016 --> Feb 2020 Recruiting --> Completed | N=120 --> 84 | Trial primary completion date: Dec 2016 --> Aug 2016
- colchicine / Generic mfg.
Enrollment change, Trial withdrawal, Adverse events: The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever. (clinicaltrials.gov) - Oct 7, 2016
P=N/A, N=0, Withdrawn, Sponsor: Rambam Health Care Campus
Recruiting --> Completed | N=120 --> 84 | Trial primary completion date: Dec 2016 --> Aug 2016 N=20 --> 0 | Not yet recruiting --> Withdrawn
- Phase classification: Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) (clinicaltrials.gov) - Oct 7, 2016
P1b, N=15, Completed, Sponsor: TransDerm, Inc.
N=20 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P1/2 --> P1b
- |||| Ilaris (canakinumab) / Novartis
Trial primary completion date: CLUSTER: Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (clinicaltrials.gov) - Sep 23, 2016
P3, N=204, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P1/2 --> P1b Trial primary completion date: Oct 2017 --> Jun 2017
- Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, IO biomarker: The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis (clinicaltrials.gov) - Sep 16, 2016
P=N/A, N=0, Withdrawn, Sponsor: Mead Johnson Nutrition
Trial primary completion date: Oct 2017 --> Jun 2017 N=240 --> 0 | Initiation date: Apr 2015 --> Sep 2013 | Terminated --> Withdrawn | Trial primary completion date: Nov 2015 --> Nov 2014
- Enrollment change, Trial primary completion date: IPCRR: International Pachyonychia Congenita Research Registry (clinicaltrials.gov) - Sep 16, 2016
P=N/A, N=1800, Recruiting, Sponsor: Pachyonychia Congenita Project
N=240 --> 0 | Initiation date: Apr 2015 --> Sep 2013 | Terminated --> Withdrawn | Trial primary completion date: Nov 2015 --> Nov 2014 N=1500 --> 1800 | Trial primary completion date: Dec 2028 --> Dec 2058
- Orfadin (nitisinone) / Astellas, SOBI
Enrollment closed, Enrollment change, Trial primary completion date: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Sep 16, 2016
P1/2, N=5, Active, not recruiting, Sponsor: National Eye Institute (NEI)
N=1500 --> 1800 | Trial primary completion date: Dec 2028 --> Dec 2058 Recruiting --> Active, not recruiting | N=50 --> 5 | Trial primary completion date: Dec 2016 --> Dec 2017
- Trial completion: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=46, Completed, Sponsor: University of Rochester
Recruiting --> Active, not recruiting | N=50 --> 5 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Enrollment change: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Jun 29, 2016
P2, N=11, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=23 --> 11
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial termination, Trial primary completion date: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 20, 2016
P2, N=147, Terminated, Sponsor: Bayer
Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> May 2016; Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat.
- Trial primary completion date: Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (clinicaltrials.gov) - May 6, 2016
P=N/A, N=10, Recruiting, Sponsor: Wake Forest University
On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat. Trial primary completion date: Dec 2015 --> Dec 2016
- triamcinolone acetonide topical / Generic mfg.
Trial primary completion date, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - May 6, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Wake Forest University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jun 2016 --> Oct 2016
- | MRX 6 / Akari Therap
Trial termination, Trial primary completion date: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (clinicaltrials.gov) - May 6, 2016
P2, N=73, Terminated, Sponsor: Celsus Therapeutics PLC
Trial primary completion date: Jun 2016 --> Oct 2016 Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Mar 2015; Interim analysis showed lack of efficacy
- |||| lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Trial completion: TREBLE: A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - May 6, 2016
P2, N=212, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Mar 2015; Interim analysis showed lack of efficacy Recruiting --> Completed
- || Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RISE-IIP: Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (clinicaltrials.gov) - May 5, 2016
P2, N=135, Recruiting, Sponsor: Bayer
Recruiting --> Completed Trial primary completion date: Jan 2017 --> Oct 2016
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) - May 3, 2016
P2, N=6, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Trial primary completion date: Jan 2017 --> Oct 2016 Active, not recruiting --> Completed
- ||||| Ilaris (canakinumab) / Novartis
Enrollment closed, Trial primary completion date: CLUSTER: Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (clinicaltrials.gov) - Apr 21, 2016
P3, N=204, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Oct 2017
- Trial primary completion date: Assessing Risk of Food Insecurity Within Households of Children With Food Allergy (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=650, Enrolling by invitation, Sponsor: Arkansas Children's Hospital Research Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- || Ilaris (canakinumab) / Novartis
Trial completion: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Apr 14, 2016
P3, N=17, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Completed
- Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=2600, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2016
- Trial primary completion date, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- recombinant ectodysplasin A1 (APO200) / Onxeo, Pierre Fabre
Enrollment closed: ECP-002e: Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002 (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=10, Active, not recruiting, Sponsor: Edimer Pharmaceuticals
Trial primary completion date: Mar 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- tacrolimus topical / Generic mfg.
Trial completion, Adherence: Protopic Adherence and Efficacy in Korean Eczema Patient (clinicaltrials.gov) - Mar 30, 2016
P=N/A, N=50, Completed, Sponsor: Pusan National University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion, Monotherapy: SOLO 1: Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2016
P3, N=674, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Ilaris (canakinumab) / Novartis
Trial completion, Enrollment change: B-Confident: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (clinicaltrials.gov) - Mar 28, 2016
P=N/A, N=288, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed | N=200 --> 288
- Trial completion, Enrollment change, Trial primary completion date: Photocil (Topical) for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Mar 25, 2016
P=N/A, N=7, Completed, Sponsor: Applied Biology, Inc.
Recruiting --> Completed | N=200 --> 288 Recruiting --> Completed | N=50 --> 7 | Trial primary completion date: Jul 2014 --> Dec 2014
- Enrollment change: The Effects of Probiotics in Atopic Dermatitis (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Recruiting --> Completed | N=50 --> 7 | Trial primary completion date: Jul 2014 --> Dec 2014 N=56 --> 0
- Trial completion: Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients (clinicaltrials.gov) - Mar 16, 2016
P3, N=30, Completed, Sponsor: Mahidol University
N=56 --> 0 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Cognitive Behavior Therapy for Atopic Dermatitis (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=9, Completed, Sponsor: Karolinska Institutet
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=25 --> 9
- |||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Enrollment change: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Feb 29, 2016
P2, N=306, Completed, Sponsor: MedImmune LLC
Active, not recruiting --> Completed | N=25 --> 9 Active, not recruiting --> Completed | N=184 --> 306
- || AIMab7195 / Nestle
Enrollment closed: Safety and Tolerability of XmAb (clinicaltrials.gov) - Feb 10, 2016
P1, N=72, Active, not recruiting, Sponsor: Xencor, Inc.
Active, not recruiting --> Completed | N=184 --> 306 Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date: Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) (clinicaltrials.gov) - Feb 4, 2016
P1/2, N=15, Completed, Sponsor: TransDerm, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - Jan 25, 2016
P2/3, N=33, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015 Trial primary completion date: Dec 2015 --> Mar 2015
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment change: CHRONOS: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2016
P3, N=739, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Dec 2015 --> Mar 2015 N=1478 --> 739
- Kineret (anakinra) / SOBI
Trial completion, Enrollment change: Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Jan 21, 2016
P3, N=25, Completed, Sponsor: Sheba Medical Center
N=1478 --> 739 Recruiting --> Completed | N=50 --> 25
- recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
Trial completion, IO biomarker: Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) - Jan 20, 2016
P2, N=6, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed | N=50 --> 25 Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Jan 19, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: University of Rochester
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2016
- triamcinolone acetonide topical / Generic mfg.
Biomarker, Trial primary completion date, IO biomarker, Biopsy: GNE-AD: A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (clinicaltrials.gov) - Jan 17, 2016
P4, N=15, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- Enrollment change: BAMBOO: Management of Eczema by Specific Probiotic Strains (clinicaltrials.gov) - Jan 16, 2016
P3, N=0, Withdrawn, Sponsor: Agentschap NL
Trial primary completion date: Jun 2015 --> Jun 2016 N=120 --> 0
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
Enrollment change: CHRONOS: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 15, 2016
P3, N=1478, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=120 --> 0 N=739 --> 1478
- ||||||| Eucrisa (crisaborole) / Pfizer
Trial completion, Trial primary completion date: CORE 2: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Dec 30, 2015
P3, N=764, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
N=739 --> 1478 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015
- ||||||| Eucrisa (crisaborole) / Pfizer
Trial completion, Trial primary completion date: CORE 1: Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis (clinicaltrials.gov) - Dec 30, 2015
P3, N=763, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015
- ||| Trial completion, Enrollment change, Trial primary completion date: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=126, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015 Active, not recruiting --> Completed | N=90 --> 126 | Trial primary completion date: Jul 2014 --> Sep 2015
- Trial primary completion date: Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=40, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed | N=90 --> 126 | Trial primary completion date: Jul 2014 --> Sep 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- Trial primary completion date: Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=10, Recruiting, Sponsor: Wake Forest University
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- triamcinolone acetonide topical / Generic mfg.
Trial primary completion date, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Wake Forest University
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Jun 2015 --> Jun 2016